AUSTIN, Texas, Oct. 2, 2024 /PRNewswire/ -- Ambetter from Superior HealthPlan, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Texans a variety of affordable health insurance plans for plan year 2025. Open enrollment for the Health Insurance Marketplace for Texas runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Since 2014, Ambetter from Superior HealthPlan has provided Texans with access to quality and affordable healthcare," said Plan President and Chief Executive Officer of Superior HealthPlan, Mark Sanders. "In 2025, we're proud to continue offering a wide variety of benefits to meet the healthcare needs of those we serve."
Ambetter from Superior HealthPlan offers its members access to quality care, convenient services, and valuable rewards. 2025 benefits and offerings include:
Below is a full list of counties in which Ambetter from Superior HealthPlan will be offered in 2025:
Texas residents interested in learning more about Ambetter from Superior HealthPlan or enrolling in a health plan during the open enrollment period may visit Ambetter.SuperiorHealthPlan.com.
About Ambetter from Superior HealthPlan
Ambetter from Superior HealthPlan serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Superior HealthPlan includes exclusive provider organization (EPO) products that are underwritten by Celtic Insurance Company, and HMO products that are underwritten by Superior HealthPlan, Inc. These companies are each Qualified Health Plan issuers in Texas. For more information, visit ambetter.com/en/tx/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Superior HealthPlan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$63.52 |
Daily Change: | 1.74 2.82 |
Daily Volume: | 5,286,820 |
Market Cap: | US$33.410B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB